Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Hematologic Diseases 1Agammaglobulinemia 1

Interventions

Cyclophosphamide 146Rituximab 138fludarabine phosphate 111Mycophenolic Acid 69Peripheral Blood Stem Cell Transplantation 63fludarabine 59Tacrolimus 58Whole-Body Irradiation 51venetoclax 46Busulfan 46ibrutinib 45Cyclosporine 42Lenalidomide 41Filgrastim 41Alemtuzumab 41Melphalan 40Radiotherapy 39obinutuzumab 37Antilymphocyte Serum 35Etoposide 33Methotrexate 32ofatumumab 29acalabrutinib 26Bendamustine Hydrochloride 24sargramostim 22Methylprednisolone 18Cytarabine 18zanubrutinib 17Pentostatin 17Granulocyte Colony-Stimulating Factor 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphocytic, Chronic, B-Cell × SARS-CoV-2 inactivated vaccines × Clear all
NCT01924169 2018-09-20

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Hematologic Diseases, Influenza, Human, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡